Company: HURA
Filing Date: 2025-05-13
Form Type: 425
Source: 0000950170-25-069822
Chunk: 0

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-13
Form: 425
Chunk 0
---
Filed pursuant to Rule 425 under the
Securities Act of 1933, as amended, and
deemed filed under Rule 14a-12 under the
Securities Exchange Act of 1934, as amended

Filer: TuHURA Biosciences, Inc.
Filer’s Commission File No.: 001-37823

Subject Company: Kineta, Inc.
Commission File No.: 001-37695

<div align='center'>TuHURA Biosciences, Inc. to Present at the 3rdAnnual H.C. Wainwright BioConnect Conference</div>

TAMPA, Fla., May 13, 2025 - TuHURA Biosciences, Inc.(NASDAQ:HURA) (“TuHURA”), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will present a company overview, including highlights of its IFx-Hu2.0 Phase 3 program, and its first-in-class bi-specific immune modulating Antibody drug, or peptide conjugates (ADCs, APCs) targeting Myeloid Derived Suppressor Cells (MDSCs), along with Kineta Inc’s. VISTA inhibiting monoclonal antibody program, at the 3rdAnnual H.C. Wainwright BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 2:30 PM ET.

In addition to the presentation, management will be available to participate in one-on-one in-person meetings with qualified members of the investor community who are registered to attend the conference. For more information about the event, please visit the conference website.

A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website (tuhurabio.com), and is also accessiblehere.

As previously announced, on December 11, 2024, TuHURA entered into a definitive agreement with Kineta, Inc. (OTC Pink: KANT) (“Kineta”) in which, as amended, TuHURA agreed to acquire Kineta, including the rights to Kineta’s novel KVA12123 antibody, for a combination of cash and shares of TuHURA common stock via a merger transaction upon the terms and conditions described in TuHURA’s Forms 8-K filed on December 12, 2024 and May 7